Jaguar Health Inc (NASDAQ:JAGX)’s share price traded up 7.9% on Friday . The stock traded as high as $0.81 and last traded at $0.79, 436,282 shares traded hands during mid-day trading. A decline of 13% from the average session volume of 504,344 shares. The stock had previously closed at $0.73.
Several research analysts recently weighed in on the company. Zacks Investment Research lowered Jaguar Health from a “hold” rating to a “sell” rating in a research report on Tuesday. LADENBURG THALM/SH SH began coverage on Jaguar Health in a research report on Thursday, September 12th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright set a $10.00 price target on Jaguar Health and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Finally, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.
The firm has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.70. The firm has a market capitalization of $36.63 million, a PE ratio of 0.00 and a beta of 0.77. The company has a quick ratio of 0.24, a current ratio of 0.35 and a debt-to-equity ratio of 0.02.
In other news, Director James J. Bochnowski purchased 180,582 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $361,164.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.81% of the company’s stock.
An institutional investor recently bought a new position in Jaguar Health stock. Wedbush Securities Inc. acquired a new stake in Jaguar Health Inc (NASDAQ:JAGX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned approximately 0.05% of Jaguar Health at the end of the most recent quarter. Institutional investors and hedge funds own 0.06% of the company’s stock.
Jaguar Health Company Profile (NASDAQ:JAGX)
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
Further Reading: Options Trading – Understanding Strike Price
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.